Abstract
The polycystic ovary syndrome (PCOS), a common endocrine disorder, is mainly related to infertility. Moreover, it is characterized by promoted androgen, suppressed ovulation and insulin resistance. Long non-coding RNA X inactive specific transcript (lncRNA XIST), known as an oncogene or a cancer inhabited factor, is involved in several disease. However, the diagnostic mechanisms of lncRNA XIST in PCOS have not been clarified. Our study aimed to explain whether lncRNA XIST regulates KGN cells proliferation and apoptosis via microRNA (miR)-212-3p/RASA1 axis in PCOS. Levels of lncRNA XIST, miR-212-3p and RASA1 in KGN cells were detected through reverse transcription quantitative polymerase chain reaction (RT-qPCR) assay. Fluorescence in situ Hybridization (FISH) was performed to confirm the expression of lncRNA XIST and miR-212-3p in KGN cells. StarBase and dual-luciferase reporter assay were applied for exploring the interaction between miR-212-3p and RASA1. Cell viability, apoptosis, protein expression of Bcl-2 and Bax were assessed by MTT, flow cytometry analysis, RT-qPCR and western blot, respectively. We found that lncRNA XIST was low-expressed, miR-212-3p was over-expressed, and RASA1 was dramatically down-regulated in KGN cells. LncRNA XIST negatively regulated miR-212-3p expression in KGN cells. MiR-212-3p interacted with RASA1 and negatively regulated RASA1 levels in KGN cells. Up-regulation of lncRNA XIST signally decreased cells viability, stimulated more apoptotic cells, enhanced Bax expression, and depressed Bcl-2 level in KGN cells. However, these observations were abolished after miR-212-3p mimic treatment. Furthermore, miR-212-3p inhibitor significantly inhibited cell proliferation, enhanced more apoptotic cells, increased Bax expression, and decreased Bcl-2 level in KGN cells, and these effects were eliminated by RASA1-siRNA transfection. Our observations revealed that lncRNA XIST protects against PCOS through regulating miR-212-3p/RASA1 axis, suggesting that lncRNA XIST may be a promising therapeutic target for PCOS therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
Belenkaia LV, Lazareva LM, Walker W, Lizneva DV, Suturina LV (2019) Criteria, phenotypes and prevalence of polycystic ovary syndrome. Minerva Ginecol 71(3):211–223. https://doi.org/10.23736/S0026-4784.19.04404-6
Cena H, Chiovato L, Nappi RE (2020) Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists. J Clin Endocrinol Metab 105(8):e2695–e2709. https://doi.org/10.1210/clinem/dgaa285
Chen X, Koivuaho E, Piltonen TT, Gissler M, Lavebratt C (2021) Association of maternal polycystic ovary syndrome or anovulatory infertility with obesity and diabetes in offspring: a population-based cohort study. Hum Reprod 36(8):2345–2357. https://doi.org/10.1093/humrep/deab112
Cheng Q, Wang L (2020) LncRNA XIST serves as a ceRNA to regulate the expression of ASF1A, BRWD1M, and PFKFB2 in kidney transplant acute kidney injury via sponging hsa-miR-212-3p and hsa-miR-122-5p. Cell Cycle 19(3):290–299. https://doi.org/10.1080/15384101.2019.1707454
Dang Y, Liu T, Yan J, Reinhardt JD, Yin C, Ye F, Zhang G (2020) Gastric cancer proliferation and invasion is reduced by macrocalyxin C via activation of the miR-212-3p/Sox6 Pathway. Cell Signal 66:109430. https://doi.org/10.1016/j.cellsig.2019.109430
Deswal R, Narwal V, Dang A, Pundir CS (2020) The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci 13(4):261–271. https://doi.org/10.4103/jhrs.JHRS_95_18
Farzaneh M, Nasrolahi A, Ghaedrahmati F, Masoodi T, Najafi S, Sheykhi-Sabzehpoush M, Dari MAG, Radoszkiewicz K, Uddin S, Azizidoost S, Khoshnam SE (2023) Potential roles of lncRNA-XIST/miRNAs/mRNAs in human cancer cells. Clin Transl Oncol 25(7):2015–2042. https://doi.org/10.1007/s12094-023-03110-y
Garo LP, Ajay AK, Fujiwara M, Gabriely G, Raheja R, Kuhn C, Kenyon B, Skillin N, Kadowaki-Saga R, Saxena S, Murugaiyan G (2021) MicroRNA-146a limits tumorigenic inflammation in colorectal cancer. Nat Commun 12(1):2419. https://doi.org/10.1038/s41467-021-22641-y
Hu J, Wang L, Chen J, Gao H, Zhao W, Huang Y, Jiang T, Zhou J, Chen Y (2018) The circular RNA circ-ITCH suppresses ovarian carcinoma progression through targeting miR-145/RASA1 signaling. Biochem Biophys Res Commun 505(1):222–228. https://doi.org/10.1016/j.bbrc.2018.09.060
Hunter A, Vimplis S, Sharma A, Eid N, Atiomo W (2007) To determine whether first-degree male relatives of women with polycystic ovary syndrome are at higher risk of developing cardiovascular disease and type II diabetes mellitus. J Obstet Gynaecol 27(6):591–596. https://doi.org/10.1080/01443610701497520
Liu M, Zhu H, Li Y, Zhuang J, Cao T, Wang Y (2020) Expression of serum lncRNA-Xist in patients with polycystic ovary syndrome and its relationship with pregnancy outcome. Taiwan J Obstet Gynecol 59(3):372–376. https://doi.org/10.1016/j.tjog.2020.03.006
Liu L, Jiang H, Pan H, Zhu X (2021a) LncRNA XIST promotes liver cancer progression by acting as a molecular sponge of miR-200b-3p to regulate ZEB1/2 expression. J Int Med Res 49(5):3000605211016211. https://doi.org/10.1177/03000605211016211
Liu X, Yang B, Zhang Y, Guo X, Yang Q, Liu X, Bai Q, Lu Q (2021b) miR-30a-5p inhibits osteogenesis and promotes periodontitis by targeting Runx2. BMC Oral Health 21(1):513. https://doi.org/10.1186/s12903-021-01882-9
Motahari Rad H, Mowla SJ, Ramazanali F, Rezazadeh VM (2022) Characterization of altered microRNAs related to different phenotypes of polycystic ovarian syndrome (PCOS) in serum, follicular fluid, and cumulus cells. Taiwan J Obstet Gynecol 61(5):768–779. https://doi.org/10.1016/j.tjog.2022.05.013
Osibogun O, Ogunmoroti O, Michos ED (2020) Polycystic ovary syndrome and cardiometabolic risk: opportunities for cardiovascular disease prevention. Trends Cardiovasc Med 30(7):399–404. https://doi.org/10.1016/j.tcm.2019.08.010
Pourteymour FTZ, Miraj S, Tahmasebian S, Ghasemi S (2020) Plasma Levels of miR-27a, miR-130b, and miR-301a in Polycystic Ovary Syndrome. Int J Mol Cell Med 9(3):198–206. https://doi.org/10.22088/IJMCM.BUMS.9.3.198
Simion V, Haemmig S, Feinberg MW (2019) LncRNAs in vascular biology and disease. Vascul Pharmacol 114:145–156. https://doi.org/10.1016/j.vph.2018.01.003
Sulistiyowati I, Yunus J, Sari D, Arfian NU (2020) pregulation of p16, Bax and Bcl-2 mRNA expression associated with epithelial apoptosis and myofibroblast proliferation in kidney fibrosis model in mice. Malays J Med Sci 27(2):37–44. https://doi.org/10.21315/mjms2020.27.2.4
Wang C, Yue S, Jiang Y, Mao Y, Zhao Z, Liu X, Zhang X, Pei D, Li Y (2020) LncRNA GAS5 is upregulated in polycystic ovary syndrome and regulates cell apoptosis and the expression of IL-6. J Ovarian Res 13(1):145. https://doi.org/10.1186/s13048-020-00748-y
Wei W, Liu Y, Lu Y, Yang B, Tang L (2017) LncRNA XIST Promotes Pancreatic Cancer Proliferation Through miR-133a/EGFR. J Cell Biochem 118(10):3349–3358. https://doi.org/10.1002/jcb.25988
Wu Z, Yu B, Jiang L (2020) MiR-212-3p mediates apoptosis and invasion of esophageal squamous cell carcinoma through inhibition of the WNT/beta-catenin signaling pathway by targeting SOX4. J Thorac Dis 12(8):4357–4367. https://doi.org/10.21037/jtd-20-2558
Xu X, Zhou X, Chen Z, Gao C, Zhao L, Cui Y (2020) Silencing of lncRNA XIST inhibits non-small cell lung cancer growth and promotes chemosensitivity to cisplatin. Aging (albany NY) 12(6):4711–4726. https://doi.org/10.18632/aging.102673
Yang H, Xie Y, Yang D, Ren D (2017) Oxidative stress-induced apoptosis in granulosa cells involves JNK, p53 and Puma. Oncotarget 8(15):25310–25322. https://doi.org/10.18632/oncotarget.15813
Yu L, Sun Y, Chu Z (2021) MiR-212-3p promotes proliferation and migration of trophoblast in fetal growth restriction by targeting placental growth factor. Bioengineered 12(1):5655–5663. https://doi.org/10.1080/21655979.2021.1967069
Zang RK, Ma JB, Liang YC, Wang Y, Hu SL, Zhang Y, Dong W, Zhang W, Hu LK (2021) MicroRNA-124 inhibits proliferation and metastasis of esophageal cancer via negatively regulating NRP1. Eur Rev Med Pharmacol Sci 25(6):2457. https://doi.org/10.26355/eurrev_202103_25392
Zhao J, Huang J, Geng X, Chu W, Li S, Chen ZJ, Du Y (2019) Polycystic ovary syndrome: novel and hub lncRNAs in the insulin resistance-associated lncRNA-mRNA network. Front Genet 10:772. https://doi.org/10.3389/fgene.2019.00772
Zhen J, Li J, Li X, Wang X, Xiao Y, Sun Z, Yu Q (2021) Downregulating lncRNA NEAT1 induces proliferation and represses apoptosis of ovarian granulosa cells in polycystic ovary syndrome via microRNA-381/IGF1 axis. J Biomed Sci 28(1):53. https://doi.org/10.1186/s12929-021-00749-z
Zheng W, Li J, Zhou X, Cui L, Wang Y (2020) The lncRNA XIST promotes proliferation, migration and invasion of gastric cancer cells by targeting miR-337. Arab J Gastroenterol 21(3):199–206. https://doi.org/10.1016/j.ajg.2020.07.010
Zheng Y, Bian Y, Wu R, Chen W, Fu L, Li P, Wang Y, Yang X, Zhao S, Shi Y (2021a) High-throughput sequencing profiles about lncRNAs and mRNAs of ovarian granulosa cells in polycystic ovary syndrome. Front Med (lausanne) 8:741803. https://doi.org/10.3389/fmed.2021.741803
Zheng H, Zhang M, Ke X, Deng X, Li D, Wang Q, Yan S, Xue Y, Wang Q (2021b) LncRNA XIST/miR-137 axis strengthens chemo-resistance and glycolysis of colorectal cancer cells by hindering transformation from PKM2 to PKM1. Cancer Biomark 30(4):395–406. https://doi.org/10.3233/CBM-201740
Acknowledgements
Not applicable.
Funding
This study was supported by 2023 Qiqihar City Science and Technology Plan Joint Guidance Research Project (grant no. LSFGG-2023021).
Author information
Authors and Affiliations
Contributions
XX: Conceptualization, Formal analysis, Project administration, Writing-original draft, and Writing-review & editing. CY, BD, and YL: Investigation, Methodology, Software, and Validation. SL and JC: Investigation and Visualization. All authors have read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interest
The authors declare that they have no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Xu, X., Yin, C., Dong, B. et al. LncRNA XIST Protects Against Polycystic Ovary Syndrome via the Regulation of miR-212-3p/RASA1 Axis. Biochem Genet (2024). https://doi.org/10.1007/s10528-024-10777-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10528-024-10777-7